Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors
Retrieved on:
Friday, June 4, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical trials, Cancer, Pancreatic cancer, Clinical medicine, Health, Neuroendocrine tumor, Neuroendocrinology, Endocrine oncology, Pancreatic neuroendocrine tumor, Somatostatin receptor 2, Evofosfamide, PEN-221, Tarveda Therapeutics®, Inc., PEN-221, TARVEDA THERAPEUTICS®, INC.
Gastrointestinal neuroendocrine tumors are a disease with a significant unmet need.
Key Points:
- Gastrointestinal neuroendocrine tumors are a disease with a significant unmet need.
- This approach demonstrated encouraging efficacy results in the GI mid-gut NET cohort of the Phase 2 trial and was well tolerated by patients.
- SSTR2 is overexpressed on the cell surface of a range of solid tumors including neuroendocrine tumors and small cell lung cancers.
- PEN-221 is being evaluated in Phase 2a expansion cohorts enrolling patients with mid-gut neuroendocrine tumors, pancreatic neuroendocrine tumors, and small cell lung cancer (ClinicalTrials.gov Identifier: NCT02936323 ).